Compare AVTX & PTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVTX | PTA |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United States |
| Employees | 33 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.6M | 984.4M |
| IPO Year | 2015 | N/A |
| Metric | AVTX | PTA |
|---|---|---|
| Price | $16.51 | $17.91 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $40.57 | N/A |
| AVG Volume (30 Days) | ★ 856.9K | 217.8K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.31% |
| EPS Growth | ★ 72.07 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,813,137.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $10.70 | $17.52 |
| 52 Week High | $24.27 | $20.92 |
| Indicator | AVTX | PTA |
|---|---|---|
| Relative Strength Index (RSI) | 39.35 | 39.11 |
| Support Level | $15.29 | $17.52 |
| Resistance Level | $16.80 | $19.61 |
| Average True Range (ATR) | 1.00 | 0.21 |
| MACD | -0.20 | 0.02 |
| Stochastic Oscillator | 23.14 | 41.90 |
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its main investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.